|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | UCB, Inc. |
|---|---|
| Information provided by: | UCB, Inc. |
| ClinicalTrials.gov Identifier: | NCT00139867 |
Purpose
The objective of this trial was to assess subject preference for PARCOPA, carbidopa/levodopa Orally Disintegrating Tablets (ODT), compared with conventional carbidopa/levodopa tablets, in subjects with stable Parkinson's disease.
| Condition | Intervention | Phase |
|---|---|---|
|
Parkinson's Disease |
Drug: PARCOPA |
Phase III |
| Study Type: | Interventional |
| Study Design: | Randomized, Open Label, Dose Comparison, Crossover Assignment |
| Official Title: | A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | SP780 |
| Study First Received: | August 29, 2005 |
| Last Updated: | September 9, 2009 |
| ClinicalTrials.gov Identifier: | NCT00139867 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
Neurotransmitter Agents Levodopa Immunologic Factors Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Physiological Effects of Drugs Basal Ganglia Diseases Nervous System Diseases Carbidopa Adjuvants, Immunologic Central Nervous System Diseases Antiparkinson Agents |
Enzyme Inhibitors Dopamine Agonists Brain Diseases Neurodegenerative Diseases Pharmacologic Actions Parkinson Disease Movement Disorders Therapeutic Uses Sinemet Dopamine Agents Parkinsonian Disorders Central Nervous System Agents |